Marinus Pharmaceuticals, Inc.
(NASDAQ:MRNS)
$7.32
0.58 (8.69%)
At Close: 4:00 PM
MRNS Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
MRNS Stock Price Today
Marinus Pharmaceuticals, Inc. (MRNS) stock rallied over 8.37% intraday to trade at $7.315 a share on NASDAQ. The stock opened with a loss of -1.04% at $6.66 and touched an intraday high of $6.71, rising 8.69% against the last close of $6.73. The Marinus Pharmaceuticals, Inc. in stock market went to a low of $6.32 during the session.
MRNS Stock Snapshot
$6.73
Prev. Close
399.18 Million
Market Cap
$6.32
Day Low
$6.66
Open
N/A
Number of Shares
$6.71
Day High
N/A
P/E ratio
-2.65
EPS (TTM)
3.23
Cash Flow per Share
N/A
Free Float in %
1.00
Book Value
361693.00
Volume
MRNS Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta1.05
Sales or Revenue$30.96 Million
5Y Sales Change171.84%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Peers
Frequently Asked Questions
What is the current Marinus Pharmaceuticals, Inc. (MRNS) stock price?
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) stock price is $7.32 in the last trading session. During the trading session, MRNS stock reached the peak price of $6.71 while $6.32 was the lowest point it dropped to. The percentage change in MRNS stock occurred in the recent session was 8.37% while the dollar amount for the price change in MRNS stock was $0.57.
MRNS's industry and sector of operation?
The NASDAQ listed MRNS is part of Biotechnology industry that operates in the broader Healthcare sector. Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders.
Who are the executives of MRNS?
Mr. Thomas J. Lyons
Senior Vice President of Corporation, Bus. Devel. & Commercial Planning
Dr. Scott N. Braunstein M.D.
Chief Executive Officer, Pres & Chairman
Ms. Sasha Damouni Ellis
Vice President of Corporation Affairs & Investor Relations
Ms. Lisa Lejuwaan
Vice President of Sales
How MRNS did perform over past 52-week?
MRNS's closing price is 1.57% higher than its 52-week low of $3.465 where as its distance from 52-week high of $11.15 is -0.05%.
How many employees does MRNS have?
Number of MRNS employees currently stands at N/A. MRNS operates from 5 Radnor Corporate Center, Radnor, PA 19087, US.
Link for MRNS official website?
Official Website of MRNS is: https://marinuspharma.com
How do I contact MRNS?
MRNS could be contacted at phone #484 801 4670 and can also be accessed through its website. MRNS operates from 5 Radnor Corporate Center, Radnor, PA 19087, US.
How many shares of MRNS are traded daily?
MRNS stock volume for the day was 361693.00 shares. The average number of MRNS shares traded daily for last 3 months was 545.59 Thousands.
What is the market cap of MRNS currently?
The market value of MRNS currently stands at $399.18 Million with its latest stock price at $7.32 and N/A of its shares outstanding.